Evidence map›Paper›PMID 35088246›Full record

Trial reportJournal of cancer survivorship : research and practice2023

Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.

Marieke van Leeuwen, Jacobien M Kieffer, Teresa E Young, Maria Antonietta Annunziata, Volker Arndt, Juan Ignacio Arraras, Didier Autran, Hira Bani Hani, Manas Chakrabarti, Olivier Chinot and 40 more

Erratum issuedOpen access · greenAbstract readClinical Trial, Phase IIIClinical Trial, Phase IV
PubMed Publisher
In one paragraph

Trial report in Journal of cancer survivorship : research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Self-reported peripheral neuropathic symptoms in long-term adolescent and young adult (AYA) cancer survivors: results of the SURVAYA study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Oral health-related quality of life among long-term head and neck cancer survivors: a multinational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Long-term health-related quality of life among adolescent and young adult breast cancer survivors.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  17. Quality of life outcomes in colorectal cancer survivors: insights from an observational study at a tertiary cancer center.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Observational
  18. Article
  19. Employment status among cancer survivors in a Late Effects Clinic in Denmark.Journal of cancer survivorship : research and practice · 2025
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

50 authors at 20 institutions in 20 countries.

Marieke van LeeuwenDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.v.leeuwen@nki.nl.ORCID http://orcid.org/0000-0003-1976-5831
Jacobien M KiefferDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Teresa E YoungLynda Jackson Macmillan Centre, North Hertfordshire NHS Trust Including Mount Vernon Cancer Centre, East &, Northwood, UK.
Maria Antonietta AnnunziataUnit of Oncological Psychology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Volker ArndtUnit of Cancer Survivorship Research, Division of Clinical Epidemiology and Aging Research & Epidemiological Cancer Registry Baden-Wurttemberg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Juan Ignacio ArrarasOncology Departments, Complejo Hospitalario de Navarra, Pamplona, Spain.
Didier AutranPole Neurosciences Cliniques, Service de Neuro-Oncologie, Aix-Marseille Universite, Marseille, France.
Hira Bani HaniKing Hussein Cancer Center, Amman, Jordan.
Manas ChakrabartiColumbia Asia Hospital, Kolkata, India.
Olivier ChinotPole Neurosciences Cliniques, Service de Neuro-Oncologie, Aix-Marseille Universite, Marseille, France.
Juhee ChoCenter for Clinical Epidemiology and Cancer Education Center, Samsung Medical Center, School of Medicine Sungkyunkwan University, Seoul, Korea.
Rene Aloisio da Costa VieiraPostgraduate Program in Oncology, Barretos Cancer Hospital, Sao Paulo, Barretos, Brazil.
Anne-Sophie DarlingtonSchool of Health Sciences, University of Southampton, Southampton, UK.
Philip R DebruyneKortrijk Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium.
Linda DirvenDepartment of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Daniela DoegeUnit of Cancer Survivorship Research, Division of Clinical Epidemiology and Aging Research & Epidemiological Cancer Registry Baden-Wurttemberg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Yannick EllerCentre for Medical Education, University of Dundee, Dundee, UK.
Martin EichlerNational Center for Tumor Diseases (NCT/UCC), University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
Nanna FridriksdottirNational University Hospital of Iceland, Ugo De Giorgi, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, 47014, Italy.
Ioannis GioulbasanisChemotherapy Department, Larissa General Clinic "E Patsidis", Athens, Greece.
Eva HammerlidDepartment of Otolaryngology, Head and Neck Surgery, Sahlgrenska University Hospital, Goteborg, Sweden.
Mieke van HemelrijckTranslational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Silke HermannEpidemiological Cancer Registry Baden-Wurttemberg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Olga HussonDivision of Clinical Studies, Institute of Cancer Research, London, UK.
Michael JeffordDepartment of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
Christoffer JohansenOncology Clinic, Finsen Center, Copenhagen Colin Johnson, University Surgical Unit, University Hospitals Southampton, Southampton, UK.
Trille Kristina KjaerSurvivorship and Inequality in Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark.
Meropi KontogianniDepartment of Nutrition & Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece.
Pernilla LagergrenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Emma Lidington, The Royal Marsden NHS Foundation Trust, London, UK.
Karolina LisyDepartment of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
Ofir MoragOncology Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Andy NordinEast Kent Gynaecological Oncology Centre, Margate, UK.
Amal S H Al OmariKing Hussein Cancer Center, Amman, Jordan.
Andrea PaceNeuroncology Unit, National Cancer Institute Regina Elena, Rome, Italy.
Silvia De PadovaPsycho-Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, 47014, Italy.
Duska PetranoviaHematology Department, University Clinical Hospital Center Rijeka, Medical Faculty University of Rijeka, Rijeka, Croatia.
Monica PintoRehabilitation Medicine Unit, Department of Strategic Health Services, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, Italy.
John RamageDepartment of Gastroenterology and Hepatology, Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK.
Elke RammantTranslational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Jaap ReijneveldDepartment of Neurology and Brain Tumor Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Samantha SerpentiniUnit of Psychoncology-Breast Unit, Istituto Oncologico Veneto (IOV)-IRCCS, Padua, Italy.
Sam SodergrenSchool of Health Sciences, University of Southampton, Southampton, UK.
Vassilios VassiliouDepartment of Radiation Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
Irma Verdonck-de LeeuwDepartment of Otolaryngology / Head & Neck Surgery, Amsterdam UMC, Amsterdam, The Netherlands.
Ingvild VistadDepartment of Gynecology and Obstetrics, Sorlandet Hospital Kristiansand, Kristiansand, Norway.
Teresa YoungLynda Jackson Macmillan Centre, Mount Vernon Cancer Centre, Northwood, UK.
Neil K AaronsonDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Lonneke V van de Poll-FranseDivision of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
EORTC QLG
The Netherlands Cancer Institute · NLGerman Cancer Research Center · DEAix-Marseille Université · FRIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITKing Hussein Cancer Center · JOKing's College London · GBMount Vernon Cancer Centre · GBPeter MacCallum Cancer Centre · AUUniversity of Southampton · GBAmsterdam Neuroscience · NLAmsterdam University Medical Centers · NLAZ Groeninge · BEBank of Cyprus Oncology Center · CYCentro di Riferimento Oncologico · ITColumbia Asia · INComplejo Hospitalario de Navarra · ESDanish Cancer Society · DKEast Kent Hospitals University NHS Foundation Trust · GBHampshire Hospitals NHS Foundation Trust · GBHarokopio University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.

methodsWe pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses. We applied the EORTC QLG decision rules and employed factor analysis and item response theory (IRT) analysis to assess and, where necessary, modify the hypothesized questionnaire scales. We calculated correlations between the survivorship scales and the QLQ-C30 summary score and carried out a Delphi survey among healthcare professionals, patient representatives, and cancer researchers to distinguish between essential and optional scales.

resultsFifty-four percent of the sample was male, mean age was 60 years, and, on average, time since completion of treatment was 3.8 years. Eleven items were excluded, resulting in the QLQ-SURV100, with 12 functional and 9 symptom scales, a symptom checklist, 4 single items, and 10 conditional items. The essential survivorship scales consist of 73 items.

conclusionsThe QLQ-SURV100 has been developed to assess comprehensively the HRQOL of disease-free cancer survivors. It includes essential and optional scales and will be validated further in an international phase IV study. IMPLICATIONS FOR CANCER SURVIVORS: The availability of this questionnaire will facilitate a standardized and robust assessment of the HRQOL of disease-free cancer survivors.

Indexed as

Cancer SurvivorsNeoplasmsHumansMaleMiddle AgedQuality of LifeSurveys and QuestionnairesSurvivorshipCancer survivorDisease-freeHealth-related quality of lifeOncologyPatient reported outcomesSurvivorship questionnaire

Identifiers

PMID35088246
OpenAlexW4210249790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.